ICCM vs. SEPA, NVNO, NSPR, SRTS, HSAQ, AMIX, APYX, XAIR, DXR, and CTSO
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include SEP Acquisition (SEPA), enVVeno Medical (NVNO), InspireMD (NSPR), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Autonomix Medical (AMIX), Apyx Medical (APYX), Beyond Air (XAIR), Daxor (DXR), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.
SEP Acquisition (NASDAQ:SEPA) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
SEP Acquisition has higher earnings, but lower revenue than IceCure Medical.
IceCure Medical has a consensus price target of $2.95, indicating a potential upside of 146.41%. Given SEP Acquisition's higher possible upside, analysts clearly believe IceCure Medical is more favorable than SEP Acquisition.
3.7% of SEP Acquisition shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 20.0% of SEP Acquisition shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
IceCure Medical received 17 more outperform votes than SEP Acquisition when rated by MarketBeat users.
SEP Acquisition has a net margin of 0.00% compared to SEP Acquisition's net margin of -453.76%. IceCure Medical's return on equity of 0.00% beat SEP Acquisition's return on equity.
In the previous week, IceCure Medical had 1 more articles in the media than SEP Acquisition. MarketBeat recorded 2 mentions for IceCure Medical and 1 mentions for SEP Acquisition. SEP Acquisition's average media sentiment score of 0.50 beat IceCure Medical's score of -1.00 indicating that IceCure Medical is being referred to more favorably in the news media.
SEP Acquisition has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Summary
IceCure Medical beats SEP Acquisition on 7 of the 13 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
